User profiles for MAURIZIO COLECCHIA
 | maurizio colecchiaVita-Salute San Raffaele University Milano Verified email at unisr.it Cited by 14089 |
[PDF][PDF] Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label …
…, S Massa, R Lucianò, M Colecchia… - Journal of Clinical …, 2018 - researchgate.net
… Andrea Necchi, Andrea Anichini, Daniele Raggi, Alberto Briganti, Simona Massa,
Roberta Lucian`o, Maurizio Colecchia, Patrizia Giannatempo, Roberta Mortarini, Marco …
Roberta Lucian`o, Maurizio Colecchia, Patrizia Giannatempo, Roberta Mortarini, Marco …
miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cε
…, M Folini, N Longoni, M Pennati, M Binda, M Colecchia… - Cancer research, 2009 - AACR
Limited information is available concerning the expression and role of microRNAs in
prostate cancer. In this study, we investigated the involvement of miR-205 in prostate …
prostate cancer. In this study, we investigated the involvement of miR-205 in prostate …
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
…, V Albertini, T Negri, A Gronchi, R Bertulli, M Colecchia… - Gastroenterology, 2004 - Elsevier
Background & Aims: Imatinib, a tyrosine kinase inhibitor of BCR-ABL, KIT, and platelet-derived
growth factor receptor, is used in patients with chronic myelogenous leukemia (CML) and …
growth factor receptor, is used in patients with chronic myelogenous leukemia (CML) and …
Imatinib mesylate in chordoma
…, C Spreafico, R Bertieri, R Bertulli, M Colecchia… - Cancer, 2004 - Wiley Online Library
BACKGROUND To the authors' knowledge, no effective medical therapy currently is available
for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐…
for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐…
[HTML][HTML] miR-21: an oncomir on strike in prostate cancer
…, V Profumo, M Callari, M Pennati, M Colecchia… - Molecular cancer, 2010 - Springer
Background Aberrant expression of microRNAs, small non-coding RNA molecules that post-transcriptionally
repress gene expression, seems to be causatively linked to the …
repress gene expression, seems to be causatively linked to the …
[HTML][HTML] Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene
…, CR Antonescu, JM Coindre, M Colecchia… - Laboratory …, 2005 - nature.com
Low-grade fibromyxoid sarcoma (LGFMS) is an indolent, late-metastasizing malignant soft-tissue
tumor that is often mistaken for either more benign or more malignant tumor types. …
tumor that is often mistaken for either more benign or more malignant tumor types. …
Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution
…, S Lo Vullo, R Bertulli, M Colecchia… - … Journal of the …, 2004 - Wiley Online Library
BACKGROUND The objective of this study was to assess long‐term prognosis and patterns
of failure in patients with retroperitoneal soft tissue sarcoma who underwent surgery with …
of failure in patients with retroperitoneal soft tissue sarcoma who underwent surgery with …
Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies
A Necchi, D Raggi, A Gallina, R Madison, M Colecchia… - European urology, 2020 - Elsevier
Background Patients with predominant variant histology (VH) of bladder tumors, defined as
involving >50 % of the tumor specimens, are typically excluded from clinical trials, and for …
involving >50 % of the tumor specimens, are typically excluded from clinical trials, and for …
The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer
…, F Brimo, JC Cheville, M Colecchia… - … of pathology & …, 2021 - meridian.allenpress.com
… Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (Colecchia) … Cheville,
Maurizio Colecchia, Eva Comperat, Isabela Werneck da Cunha, Warick Delprado, Angelo …
Maurizio Colecchia, Eva Comperat, Isabela Werneck da Cunha, Warick Delprado, Angelo …
Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three‐grade system
…, R Miceli, MW Kattan, MF Brennan, M Colecchia… - Cancer, 2005 - Wiley Online Library
BACKGROUND A nomogram for predicting long term tumor‐specific death in patients with
soft tissue sarcoma (STS) was developed at the Memorial Sloan‐Kettering Cancer Center (…
soft tissue sarcoma (STS) was developed at the Memorial Sloan‐Kettering Cancer Center (…